Cipla Q2 Results Today: Net profit up 4% YoY to Rs 1,351 crore, revenue grows 8%

Cipla Q2 Results 30th October: Cipla Ltd on Thursday reported a 4 per cent year-on-year (YoY) increase in consolidated net profit at Rs 1,351 crore for the quarter ended September 2025 (Q2FY26). The company had posted a profit of Rs 1,302.53 crore in the same period last year.

Revenue from operations rose 8 per cent YoY to Rs 7,589.44 crore, supported by steady growth across domestic and international markets.

At the time of writing, Cipla shares were trading at Rs 1,572 on the BSE, down 0.58 per cent or Rs 9.10 from the previous close.

Segment performance

The India business generated Rs 3,146 crore in revenue, up 7 per cent YoY, led by solid traction in core therapies. Cipla’s respiratory brand Foracort retained its No. 1 ranking in the domestic market.

In North America, revenues stood at $233 million, supported by continued leadership in Albuterol, which holds a 22 per cent market share in the US Albuterol MDI segment. The region’s performance was further boosted by strong growth in differentiated assets. Cipla’s Lanreotide product gained market share, rising to 22 per cent during the quarter.

The company also launched Filgrastim, its first biosimilar in the US market, marking a strategic milestone in its biosimilar portfolio expansion. During the quarter, Cipla’s manufacturing facility at Bommasandra, Bengaluru, was classified as VAI (Voluntary Action Indicated) by the U.S. FDA — a positive regulatory outcome supporting its US operations.

Outlook

Looking ahead, Cipla plans to launch four major respiratory assets by calendar year 2026, including gAdvair in Q4 FY26, along with three peptide assets such as Liraglutide. Three of these four respiratory products are being filed from Cipla’s US manufacturing sites, enhancing supply reliability and reducing regulatory risk.

Other geographies

The Africa segment reported revenues of $134 million, up 5 per cent YoY, with the South Africa private market business growing at 1.3x the market rate. The Emerging Markets and Europe segment delivered $110 million, a 15 per cent YoY increase, achieving its highest-ever quarterly revenue in the region.

Domestic portfolio highlights

Cipla maintained its second position in the overall chronic segment, with the chronic mix improving to 61.8 per cent. Key therapies such as urology, anti-diabetics, cardiac, anti-infectives, and dermatology outpaced overall market growth.

The trade generics division delivered strong growth, supported by a wider product base. Cipla now has two brands with trailing twelve-month (TTM) revenue exceeding Rs 100 crore and five brands with TTM revenue between Rs 50 crore and Rs 100 crore. The company launched six new products during the quarter, including an entry into the orthocare category.

Consumer health

The consumer health business also posted robust growth, with both anchor and transitioned brands scaling up. Flagship products Nicotex, Omnigel, and Cipladine maintained their No. 1 positions in respective categories, while EBITDA growth remained steady.